Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria to Complement Pitfalls of RECIST

AJR:198, April 2012

Mizuki Nishino Jyothi P. Jagannathan Katherine M. Krajewski Kevin O'Regan Hiroto Hatabu Geoffrey Shapiro Nikhil H. Ramaiya

OBJECTIVE. The purpose of this article is to review cancer- and therapy-specific tumor response assessment criteria used in clinical trials and in practice, with illustrative case ex­amples, and to discuss future directions toward "personalized" tumor response assessment.

CONCLUSION. Although Response Evaluation Criteria in Solid Tumors will remain as the primary generalized criteria for response assessment, newer cancer- and therapy-specific criteria will play an important role in providing state-of-the-art response assessment of tumor following molecular targeted therapy and will contribute to personalized cancer care in the era of molecular medicine.